English, Article edition: Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach Paul Fenn; Alastair Gray

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119682
Physical Description
  • article
Language
  • English

Edition details

Title
  • Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach
Author
  • Paul Fenn
  • Alastair Gray
Physical Description
  • article
Notes
  • Objective: This paper puts forward a proposal for a modelling approach to the estimation of long term cost savings from the treatment of Alzheimer's disease (AD). Design: In the proposed modelling approach, disease progression is defined in terms of intervals in the Mini-Mental State Exam (MMSE) scale. Clinical trial data are then used to determine the time at which a particular patient moved into a more severe stage of the disease. By comparing these durations across treatment groups, survival analysis is used to measure the impact of treatment in delaying the onset of a more costly stage of the disease. Setting: Patients with varying severity of AD. Patients and participants: The model uses clinical trial data on 1333 patients recruited internationally in 2 studies from 67 centres. Interventions: The aim of these clinical studies was to evaluate the safety and efficacy of 2 non-overlapping dose ranges of rivastigmine relative to placebo over a 26-week treatment period in patients with probable AD. Main outcome measures and results: The results indicate that the average cost savings with high-dose rivastigmine at the end of the trial period are quite low (approximately Lstg 29 per patient; 1997 values), but by extrapolating to a projected lifetime of 3 years, they rise to approximately Lstg 1100 per patient. The largest long term cost savings from treatment are obtained from treating those in the mild category (i.e. MMSE > 20). However, if the time horizon over which savings are estimated is short (i.e. if life expectancy is below 2 years), more costs are saved by prioritising patients with moderate AD (i.e. MMSE between 20 and 11). Conclusions: The model is a possible approach for estimating cost savings with treatment of AD, given the lack of long term data on resource use and drug efficacy. Caution should be used when extrapolating the results beyond the original study parameters.
  • Pharmacoeconomics, Alzheimer's-disease, Rivastigmine, Cost-analysis, Anticholinesterases
  • RePEc:wkh:phecon:v:16:y:1999:i:2:p:165-174
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment